How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

We recently published 12 Best Healthcare Stocks to Buy Under $30. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best healthcare stocks. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a ...

Forbes contributors publish independent expert analyses and insights. I write about the business of healthcare. This article is more than 4 years old. Chris Gibson, Co-Founder & CEO, Recursion ...

Recursion Pharmaceuticals reported significant growth in sales and revenue for Q2 and the first half of 2025 but also experienced widening net losses. The release of their Boltz-2 model underscored a ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

One person that helped bring the chill was an analyst cutting his price target. Another two were executives at the biotech selling chunks of stock. 10 stocks we like better than Recursion ...

One person that helped bring the chill was an analyst cutting his price target. Another two were executives at the biotech selling chunks of stock. The company was the target of an analyst price ...